A Field Whose Time Has Come: Launching the EULAR Study Group on Geriatric Rheumatology

Save

A substantial portion of patients seen in rheumatology clinics are now older adults living with multimorbidity, polypharmacy, frailty, cognitive impairment, functional limitation, and competing health priorities. This week at EULAR 2026 in London, the EULAR Study Group on Geriatric Rheumatology holds its inaugural meeting. The launch marks an important step for a field that has been visible in clinical practice, but less visible in professional structures.

EULAR 2026: Industry Press Releases

Save

Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic diseases.

Rheumatology Shortage Cliff in Australia & USA

Save

Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States.

ACPA and the Transition from Arthralgia to Rheumatoid Arthritis

Save

Patients with clinically suspect arthralgia (CSA), a common prequel to rheumatoid arthritis (RA), showed different patterns of symptoms and progression depending on whether they tested positive for anti-citrullinated protein antibodies (ACPA), researchers found.

Guselkumab gets FDA Nod for X-ray Protection

Save

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's supplemental Biologics License (sBLA) to include evidence in the guselkumab (Tremfya) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA). 

Count Your Telangiectasias (5.29.2026)

Save

Dr. Jack Cush reviews the news, journal articles and missed quiz questions.

Increased Polypharmacy in SLE Patients

Save

A cross-sectional study of US adults with systemic lupus erythematosus (SLE) shows significantly increased prevalence of polypharmacy, related to age, disease outcomes and often, non-SLE common medications.

Integrating D2T into T2T Practices in RA

Save

Researchers at Semmelweis University analyzed how depression, smoking, obesity, sleep disorders, and other health problems are linked to difficult-to-treat rheumatoid arthritis (D2T-RA) and how this can inform treat-to-target (T2T) and individualized therapy.

LRA Awards for Immune Resetting Therapies in Lupus

Save

Lupus Research Alliance (LRA), the world’s largest private funder of lupus research, in collaboration with Genentech, a member of the Roche Group, announced the inaugural recipients of t

WSJ: Nurse Practitioner Is Now the Hottest Job in Healthcare

Save

RepurpSS-II: Hydroxychloroquine plus Leflunomide in Sjögren's

Save

A small, pilot, phase 2b trial has shown that the combination of leflunomide and hydroxychloroquine (LEF+HCQ) was effective and safe in treating patients with active Sjögren's disease.

Trends and Innovations in Lupus Nephritis Clinical Trials

Save

Xu et al. from Shanghai University have written an analysis of global lupus nephritis (LN) clinical trials and call for innovation.

Quiz Talk (5.22.2026)

Save

Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.

BE BOLD Week 16 data - Bimekizumab vs. Risankizumab in PsA

Save

UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6.

A Role for Plasmacytoid Dendritic Cells in Lupus

Save

Plasmacytoid dendritic cells (pDCs) have been strongly implicated in the pathogenesis of lupus, as their primary product, type I interferon, drive systemic lupus erythematosus and cutaneous lupus erythematosus. A recent comprehensive review synthesizes the available data on pDCs, and, importantly, what we still don't know.